Drugdocs | Zinplava

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Zinplava

Chemical Name	bezlotoxumab
Dosage Form	Injection (intravenous; 1000 ml/40 mL)
Drug Class	Monoclonal antibodies
System	Digestive
Company	Merck & Co.
Approval Year	2016

Indication

To reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.

Last updated on 10/26/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Zinplava (bezlotoxumab) Prescribing Information	2016	Merck Sharp & Dohme Corp.

Document Title	Year	Source
Efficacy and safety of monoclonal antibodies against clostridioides difficile toxins for prevention of recurrent clostridioides difficile infection: a systematic review and meta-analysis.	2020	Journal of Clinical Gastroenterology

Document Title	Year	Source
Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).	2020	Spanish Journal of Chemotherapy